CORDIS - EU research results
CORDIS

Ferroptosis Inhibitors For Neurodegenerative Disorders

Project description

New drugs that can reach the brain

Treatment of neurological and neurodegenerative diseases such as Alzheimer’s disease requires drugs that can reach the brain. However, the blood-brain barrier poses a significant obstacle to most treatments to date. Funded by the Marie Skłodowska-Curie Actions programme, the NeuroFerro project will focus on the development of compounds that can cross the blood-brain barrier and inhibit ferroptosis in afflicted neurons. Ferroptosis is a type of cell death characterised by iron-dependent lipid peroxidation. In the brain, lipid peroxidation is linked to the pathophysiology of neurodegeneration. The improved pharmacokinetics of the NeuroFerro inhibitors will provide new treatment options to patients suffering from neurological or neurodegenerative disorders.

Objective

FERROptosis inhibitors for NEUROdegenerative disorders (NeuroFerro) will focus on the development of potent compounds with improved pharmacokinetic properties, including blood-brain barrier (BBB) permeability for future application in the treatment of neurodegenerative disorders. Ferroptosis is non-apoptotic programmed cell death that has been linked to the pathophysiological processes of many diseases, including dementia, Huntington’s disease, Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Neurological disorders are one of the most significant causes of disability-adjusted life-years and death worldwide with very limited treatment available. Although ferroptosis inhibitors developed by Augustyns and Vanden Berghe (supervisors) are currently best in class compounds, they suffer from no or minor BBB permeability. Therefore the main aim of the project will be the design and synthesis of novel ferroptosis inhibitors with improved pharmacokinetic parameters and high blood-brain barrier permeability to target ferroptosis in neurodegenerative disorders.

Funding Scheme

MSCA-PF - MSCA-PF

Coordinator

UNIVERSITEIT ANTWERPEN
Net EU contribution
€ 239 700,00
Address
PRINSSTRAAT 13
2000 Antwerpen
Belgium

See on map

Region
Vlaams Gewest Prov. Antwerpen Arr. Antwerpen
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Partners (1)